book excretion full 1 June 2021

ขอ 7.4.3.10 จากแนวทางการใหยาFamciclovir (ขอมูล Clcr ผปู วย = 45 mL/min) สรปุ ดังนี้ Indication Dosing Modifications Dose in Patients Acute herpes zoster CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs CrCl 40-59 mL/min: 500 mg q12hr CrCl 20-39 mL/min: 500 mg once daily CrCl <20 mL/min: 250 mg once daily Hemodialysis: 250 mg after each session Herpes labialis CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs CrCl 40-59 mL/min: 750 mg once CrCl 20-39 mL/min: 500 mg once CrCl <20 mL/min: 250 mg once Hemodialysis: 250 mg once after dialysis Genital herpes CrCl ≥60 mL/min: Regular dosage 500 mg q12hrs (treatment of recurrent CrCl 40-59 mL/min: 500 mg q12hr disease) for 1 day (2 doses total) CrCl 20-39 mL/min: 500 mg once CrCl <20 mL/min: 250 mg once Hemodialysis: 250 mg once after dialysis Genital herpes CrCl ≥40 mL/min: Regular dosage Regular dosage = (suppressive therapy) CrCl 20-39 mL/min: 125 mg q12hr 250 mg PO q 12hrs CrCl <20 mL/min: 125 mg/day Hemodialysis: 125 mg after each session Herpes CrCl ≥40 mL/min: Regular dosage Regular dosage = Prevention of HSV reactivation: (HIV-infected adults) CrCl 20-39 mL/min: 500 mg/day 500 mg PO q 12hrs CrCl <20 mL/min: 250 mg/day Recurrent episodes: 500 mg PO Hemodialysis: 250 mg after each 48 hrs of symptom or lesion session onset ที่มา https://reference.medscape.com/drug/famvir-famciclovir-34261 148

ดัชนี คาํ หนา คํา หนา A Edema 6 Absorption Active transport 1F 9 AHFS drug information 6, 17 ,44, 57 Alprazolam 6, 17 ,44, 57 Folic acid Atorvastatin 67 B 96 Flow llimited 4, 108 Biliary excretion Biotransformation 10, 13, 69 G 40 Bowman's capsule 10, 69, 75 Gabapentin 14 C 14, 75 Capacity limited 80 Gastric emptying time Capacity limitted binding insensitive 35 Capacity limitted binding insensitive Glomerular filtration 42 Carrier mediated transport 59 Ceftriaxone 20 Glucuronide 62 Chronopharmacokinetics 63 Chronotherapy 39 Grapefruit 59 Ciprofloxacin 40 Circadian effect H Clearance 66 Half-life 81 Clonazepam 98 Competition 66 Henderson-Hassenbach Conjugation 15 D 66 Hepatic artery 28 Diffusion 4 Hepatic clearance 15 Distribution 31, 33 ,111 Hepatic extraction ratio 8 Drug information handbook 21 E 102 Hepatocyte 6 Elimination Elimination rate constant 120 Hydrostatic pressure 9 Excretion 6, 17 ,44, 57 Exporter inhibitors 31, 108, 111 I Extraction ratio 102 Intestinal excretion 67 4, 108 20 Intracellular hydrostatic pressure 10 K 45 Ketoconazole 14 Ketoprofen L 5 Lexicom online 5 Loading dose 98 Levothyroxine Lisinopril 15 Liothyronine 28 Losartan 15 Lithium 8M 21 Mamary excretion 149

คาํ หนา คาํ หนา Medscape 100 R 23, 33 Metabolism 11 Renal clearance 96 Methotrexate 82, 84,113, 118 47 Methylation 14 Rxlist drug information Micromedex 98 7 Modified diet in renal disease (MDRD) 88 Ranitidine 81 N S 44 Naproxen 18 Sodium iodide transporter 59 Nortriptyline 13 84 O Salivary excretion 10, 13, 69-70, 72, 75 Organ clearance 21 Saturation 14 Osmotic pressure 41 Obese 7 Sinusoid 5, 17, 84 Occular permeability 118 21, 23, 50 P Sweat excretion Passive transport 4 41, 50 Pore transport 4 Simvastatin 44, 51 Periportal Hepatocyte 61 7, 69-70, 74 Perivenous 61 Sulfation Pharmacodynamics 1 T 8, 13-14, 64, 69 Pharmacokinetics 1 Tetracycline 64, 82, 105, 112, 119 Phase 1 metabolism 11 Phase 2 metabolism 11 Totalbody clearance 5, 10, 13, 64, 68 Portal vein 59 Protein binding 42 Tubular reabsorption 69 Permeability 6, 108 Q Tubular secretion 69 Quaternary ammonium 47, 81 Quinidine 8, 13-14, 64 Tramadol 68-69, 75, 82 V Quinine 13, 43, 75, 81, 106 Verapamil Valproic acid W Warfarin X Xanax Z zolpedem 150

ประวัติผเู ขียน ชือ่ -นามสกุล กรณั ฑร ตั น ทิวถนอม จฬุ าลงกรณ มหาวิทยาลยั (2551) ตําแหนง ผชู วยศาสตราจารย ดร. สถานท่ีทํางาน คณะเภสชั ศาสตร มหาวทิ ยาลัยศลิ ปากร การศกึ ษา ภด. (บรบิ าลทางเภสชั กรรม) ภม. (เภสัชกรรมคลนิ ิก) มหาวทิ ยาลยั มหิดล (2545) ภบ. มหาวิทยาลัยศลิ ปากร (2538) Scholarship and Grant 1. The University Developing Commission (UDC) Programme 1995-1998 2. Research grant from Government Pharmaceutical Organization 1996 3. The training grant for Therapeutic Drug Mornitoring from the embassy of France 1999 4. The Faculty scholarship for participating European Society of Clinical Pharmacy conference at Malta 2001. 5. The Faculty scholarship for PhD 2002-2003, at present 6. The CRN Schlolarship for PhD. 2003-2005 7. ISN travel grant 2005 8. Faculty research grant (2010) 9. University research grant (2011) 151

10. ISPOR Travel grant (2012) 11. NRCT research grant (2016) 12. Graduate research grant (2017) Publications 1. Karunrat Tewthanom, Chanudom Cherachat, Chudaporn Sukkasem, Chosita Somwangprasert, Suchima Pornbunjerd, Napa Parinyanitikul. (2018) Factor associated transtuzumab cardiotoxicity in breast cancer: a case control study. In proceeding of Unity in Diversity and the Standardization of Clinical Pharmacy Services: Proceedings of the 17th Asian Conference on Clinical Pharmacy (ACCP 2017), July 28-30, 2017, Yogyakarta, Indonesia, edited by Elida Zairina, ISBN 9781138081727. 2. Karunrat Tewthanom, Chanudom Cherachat, Chudaporn Sukkasem, Chosita Somwangprasert, Suchima Pornbunjerd. Breast cancer therapy and cardiotoxicity of Trastuzumab in Breast cancer patients. Veridian E-Journal, Science and Technology Silpakorn University. 2017:4(2) March – April; 1-18. 3. Karunrat Tewthanom. Sofosbuvir: current information for hepatitis C treatment. Thai Bull Pharm Sci. 2017; 12(1):91-107. 4. Wikawee Russameethum, Karunrat Tewthanom. Risk-benefit of high dose metformin beyond current evidence-based pharmacotherapy. Thai Bull Pharm Sci. 2017; 12(1):55-62. 5. Tewthanom K, Jongjaroenprasert W. The pharmacokinetics of 2 doses (50 mcg and 100 mcg) levothyroxine treatment in athyreotic patients. International Journal of Applied Pharmaceutics. 2016:8(4); 66-68. 6. Karunrat Tewthanom, Rinsook Ongarjsakulman, Theerarat Tankhum Lithuim Serum Level In Children; The tool for dose adjustment is needed? : Preliminary data at Yuwaprasart Waithayopathum Child Psychiatric Hospital. 26th FAPA congress 2016. 9-13 November 2016. Bangkok, Thailand 7. Karunrat Tewthanom, Experiential Learning Model in Pharmacy Orientation Course: the preliminary development activities for future trends of 21st Century of Pharmacy Education. International of Pharmacy Education and Research 2016:3(3); 1-4. 152

8. Tewthanom K. “The screening of skin carotenoid concentration (SCC) in patients with cardiovascular disease and Diabetes Mellitus: An association assessmentin single study.” In Proceeding of 14th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology 2015. Rotterdam, Netherland, October 11-15, 2015. 9. Tewthanom K. “Cost Effectiveness Analysis among Patients with Diabetes Mellitus or Cardiovascular Diseases receiving second-line treatment with intensive dose of Simvastatin Atorvastatin and Atorvastatin-Ezetimibe combination in General Practice” In Proceeding of ISPOR 20th Annual International meeting, Philadelphia, USA, May 16-20, 2015. 10. Tewthanom K. “Cost Effectiveness Analysis of Simvastatin Atorvastatin and Atorvastatin- Ezetimibe combination among Patients with Diabetes Mellitus or Cardiovascular Diseases in General Practice.” In Proceeding of ISPOR 20th Annual International meeting, Philadelphia, USA, May 16-20, 2015. 11. Tewthanom K, Rattanakunooprakarn H. Factor affecting the assessment of the cost effectiveness of statins in the primary prevention of coronary heart disease. Journal of TBPS 2014; 9,1: 38-56. 12. Duangmee K, Phetsai C, Khunthongphet U, Sengsoon N, Tewthanom K. Study of relationship between trigger tools and adverse drug event at Somdet Phra Sangharaja the 19 th hospital, Kanchanaburi. Conference: The 25th FAPA Congress 2014 in Malaysian Journal of Pharmacy, At Kotakinabalu Malaysia, Malaysian Journal Volume: 1 13. Tewthanom K, Chaiwirattana N, Saelim W et al. Hypertensive medication discrepancies at the time of hospital admission: the initiative problem’s survey process in community hospital setting. J Pharm Biomed Sci. 2013; 26:406-09. 153